皇家眼科医师学院与英国青光眼学会青光眼风险分层工具GLAUC-STRAT-fast的验证
本研究将皇家眼科医师学院推荐的GLAUC-STRAT-fast风险分层工具应用于LiGHT试验参与者,对每例患者基线时及治疗3年后的较差眼进行风险分层。结果显示基线分层与维持眼特异性目标眼压所需的治疗升级次数、3年随访期间所需就诊次数、需行小梁切除术及监测期间视野平均偏差绝对丢失相关,但视野进展速率与基线风险分层无显著关联。
要点
- 基线风险分层与治疗升级次数(p=0.001)、随访就诊次数(p=0.001)相关。
- 基线风险分层与需行小梁切除术(p<0.001)、视野平均偏差绝对丢失(p<0.001)相关。
- 总偏差或模式偏差定义的视野进展速率与基线风险分层无显著关联(p≥0.007,Bonferroni校正)。
核心结论
- GLAUC-STRAT-fast工具可用于对高眼压症或开角型青光眼患眼进行风险分层。
- 需进一步研究以确认并验证该工具对更晚期青光眼的适用性及临床使用的可推广性。
研究设计与样本
- 验证性研究,将GLAUC-STRAT-fast应用于LiGHT试验参与者,对每例患者基线时及治疗3年后的较差眼进行风险分层。
主要发现
- 基线分层与维持眼特异性目标眼压所需的治疗升级次数相关(p=0.001)。
- 基线分层与3年随访期间所需就诊次数相关(p=0.001)。
- 基线分层与需行小梁切除术相关(p<0.001)。
- 基线分层与监测期间视野平均偏差绝对丢失相关(p<0.001)。
- 总偏差或模式偏差定义的视野进展速率与基线风险分层无显著关联(p≥0.007,Bonferroni校正)。
关键数值与推荐
- 验证所用疾病严重度或治疗强度指标包括:监测就诊次数增加或治疗升级、需行小梁切除术、监测期间视野平均偏差下降>2 dB、总偏差和/或模式偏差识别出快速视野丢失。
- 各基线分层内上述各指标的眼比例与其他分层比较,采用χ2检验比较比例。
局限性
- 需进一步研究以确认并验证该工具对更晚期青光眼的适用性及临床使用的可推广性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: The aim of this study was to validate the Glaucoma Risk Stratification Tool (GLAUC-STRAT-fast) currently recommended by the Royal College of Ophthalmologists for the risk stratification of patients with glaucoma in the UK National Health Service Hospital Eye Service. METHODS: GLAUC-STRAT fast was applied to the LiGHT trial participants by risk-stratifying the worse eye of each patient at baseline and after 3 years of treatment. Metrics of disease severity or treatment intensity used for the validation were: increased number of monitoring visits or treatment escalations; needing a trabeculectomy; a reduction of >2 dB in visual field mean deviation (VF MD) during the monitoring period; identification of rapid VF loss on total (TD) and/or pattern deviation (PD). The proportion of eyes within each baseline stratum for each of the above markers was compared against the other strata, using a χ2 test for proportions. RESULTS: There was an association between the baseline stratification and the number of treatment escalations needed to maintain the eye-specific target intraocular pressure (p=0.001), the number of visits needed throughout the 3-year follow-up period (p=0.001), the need for trabeculectomy (p<0.001) and absolute loss of MD over the course of the monitoring period (p<0.001). The rate of VF progression was not associated with baseline risk stratification for TD or PD progression (p≥0.007, with Bonferroni correction). CONCLUSION: The GLAUC-STRAT fast tool is a useful tool for risk stratifying eyes with ocular hypertension or open angle glaucoma. Further research is needed to confirm and validate its applicability to more advanced glaucomas and generalisability to clinical use. TRIAL REGISTRATION NUMBER: The LiGHT trial is registered at controlled-trials.com (ISRCTN32038223).
引用
- Konstantakopoulou E, Kastner A, Gazzard G, et al. Validation of the RCOphth and UKEGS glaucoma risk stratification tool 'GLAUC-STRAT-fast'. Br J Ophthalmol. 2022. PMID: 35534178. doi:10.1136/bjophthalmol-2021-320968
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。